Amrubicin (AMR) does not reduce LVEF with cumulative doses > 1000 mg/m(2) in 2nd-line treatment of small cell lung cancer (SCLC): A pooled analysis of two phase II trials

David R. Spigel; Chirag Shah; Paul Lorigan; Richard McNally; Markus Renschler; Jennifer W. Oliver

Amrubicin (AMR) does not reduce LVEF with cumulative doses > 1000 mg/m(2) in 2nd-line treatment of small cell lung cancer (SCLC): A pooled analysis of two phase II trials

David R. Spigel, Chirag Shah, Paul Lorigan, Richard McNally, Markus Renschler, Jennifer W. Oliver

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	Undefined
Pages (from-to)	S399-S400
Number of pages	2
Journal	Journal of Thoracic Oncology
Volume	4
Issue number	9/ Supplement 1
Publication status	Published - Sept 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{4c289456ada6438fa20758e6e8caec42,

title = "Amrubicin (AMR) does not reduce LVEF with cumulative doses > 1000 mg/m(2) in 2nd-line treatment of small cell lung cancer (SCLC): A pooled analysis of two phase II trials",

author = "Spigel, {David R.} and Chirag Shah and Paul Lorigan and Richard McNally and Markus Renschler and Oliver, {Jennifer W.}",

year = "2009",

month = sep,

language = "Undefined",

volume = "4",

pages = "S399--S400",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier BV",

number = "9/ Supplement 1",

}

Amrubicin (AMR) does not reduce LVEF with cumulative doses > 1000 mg/m(2) in 2nd-line treatment of small cell lung cancer (SCLC): A pooled analysis of two phase II trials. / Spigel, David R.; Shah, Chirag; Lorigan, Paul et al.
In: Journal of Thoracic Oncology, Vol. 4, No. 9/ Supplement 1, 09.2009, p. S399-S400.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Amrubicin (AMR) does not reduce LVEF with cumulative doses > 1000 mg/m(2) in 2nd-line treatment of small cell lung cancer (SCLC)

T2 - A pooled analysis of two phase II trials

AU - Spigel, David R.

AU - Shah, Chirag

AU - Lorigan, Paul

AU - McNally, Richard

AU - Renschler, Markus

AU - Oliver, Jennifer W.

PY - 2009/9

Y1 - 2009/9

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000269496001167&KeyUID=WOS:000269496001167

M3 - Meeting Abstract

SN - 1556-0864

VL - 4

SP - S399-S400

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 9/ Supplement 1

ER -

Amrubicin (AMR) does not reduce LVEF with cumulative doses > 1000 mg/m(2) in 2nd-line treatment of small cell lung cancer (SCLC): A pooled analysis of two phase II trials

UN SDGs

Other files and links

Cite this